Press Releases

All Releases
View Summary Intellipharmaceutics Announces Closing of US$4 Million Financing
Oct 13, 2017
PDF 20.6 KB Add to Briefcase
View Summary Intellipharmaceutics Announces US$4 Million Registered Direct Offering
Oct 11, 2017
PDF 21.1 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Third Quarter 2017 Results
Oct 10, 2017
PDF 42.1 KB Add to Briefcase
View Summary Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA
Sep 25, 2017
PDF 19.7 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Receipt of Nasdaq Notice
Sep 20, 2017
PDF 20.5 KB Add to Briefcase
View Summary Intellipharmaceutics Provides Operational Update
Sep 5, 2017
PDF 22.8 KB Add to Briefcase
View Summary Intellipharmaceutics Appoints New Chief Financial Officer
Sep 1, 2017
PDF 19.8 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Resignation of Chief Financial Officer
Aug 8, 2017
PDF 18.8 KB Add to Briefcase
View Summary Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit
Jul 31, 2017
PDF 19.8 KB Add to Briefcase
View Summary Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
Jul 26, 2017
PDF 22.6 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Second Quarter 2017 Results
Jul 11, 2017
PDF 41.8 KB Add to Briefcase
View Summary Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
Jun 30, 2017
PDF 22.4 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Launch of Generic Seroquel XR® by Mallinckrodt
Jun 6, 2017
PDF 20.3 KB Add to Briefcase
View Summary Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement
May 26, 2017
PDF 20.9 KB Add to Briefcase
View Summary Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical
May 24, 2017
PDF 20.6 KB Add to Briefcase
View Summary Intellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR®
May 10, 2017
PDF 21.5 KB Add to Briefcase
View Summary Intellipharmaceutics Reports Director Election Results
Apr 18, 2017
PDF 19.9 KB Add to Briefcase
View Summary Intellipharmaceutics Announces First Quarter 2017 Results
Apr 11, 2017
PDF 42.7 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista™ Abuse-Deterrent Extended-Release Oxycodone
Apr 10, 2017
PDF 19.6 KB Add to Briefcase
View Summary Intellipharmaceutics Announces TSX Trading Symbol Change to "IPCI"
Mar 16, 2017
PDF 18.3 KB Add to Briefcase
Showing 1-20 of 159 Page: 1 2 3 ... 8  Next 20
=add release to Briefcase